Demographics of study population grouped by first HPV B19 results
. | Total population . | Cohort A* . | Cohort B† . | P‡ . |
|---|---|---|---|---|
| Total, n | 633 | 187 | 446 | |
| SCD type, n (%) | ||||
| SCD-SS | 409 (64.6) | 117 (62.5) | 292 (65.4) | |
| SCD-SC | 145 (22.9) | 43 (23.0) | 102 (22.9) | |
| SCD-Sβ+ | 58 (9.2) | 19 (10.3) | 39 (8.7) | |
| SCD-Sβ° | 18 (2.8) | 7 (3.7) | 11 (2.5) | |
| SCD-other | 3 (0.5) | 1 (0.5) | 2 (0.5) | |
| Male sex, n (%) | 335 (52.9) | 88 (47.1) | 247 (55.4) | NS |
| Median age at first HPV B19 test, y (range) | 7.3 (0.9-21.7) | 11.2 (1.1-21.7) | 5.4 (0.9-20.9) | < .001 |
| Chronic therapy, n (%) | 91 (14.4) | 13 (6.9) | 78 (17.5) | < .001 |
| Transfusion | 57 | 8 | 49 | |
| Hydroxyurea | 34 | 5 | 29 | |
| Sibling with SCD, n (%) | 147 (23.2) | 47 (25.1) | 100 (22.4) | NS |
. | Total population . | Cohort A* . | Cohort B† . | P‡ . |
|---|---|---|---|---|
| Total, n | 633 | 187 | 446 | |
| SCD type, n (%) | ||||
| SCD-SS | 409 (64.6) | 117 (62.5) | 292 (65.4) | |
| SCD-SC | 145 (22.9) | 43 (23.0) | 102 (22.9) | |
| SCD-Sβ+ | 58 (9.2) | 19 (10.3) | 39 (8.7) | |
| SCD-Sβ° | 18 (2.8) | 7 (3.7) | 11 (2.5) | |
| SCD-other | 3 (0.5) | 1 (0.5) | 2 (0.5) | |
| Male sex, n (%) | 335 (52.9) | 88 (47.1) | 247 (55.4) | NS |
| Median age at first HPV B19 test, y (range) | 7.3 (0.9-21.7) | 11.2 (1.1-21.7) | 5.4 (0.9-20.9) | < .001 |
| Chronic therapy, n (%) | 91 (14.4) | 13 (6.9) | 78 (17.5) | < .001 |
| Transfusion | 57 | 8 | 49 | |
| Hydroxyurea | 34 | 5 | 29 | |
| Sibling with SCD, n (%) | 147 (23.2) | 47 (25.1) | 100 (22.4) | NS |